Related Experiment Videos
Clinical experience with denileukin diftitox (ONTAK).
1Medical Oncology, Yale Cancer Center, New Haven, CT 06520, USA. Francine.foss@yale.edu
Seminars in Oncology
|March 7, 2006
Summary
Denileukin diftitox targets cancer cells expressing the IL-2 receptor. This fusion protein delivers diphtheria toxin to induce cell death, showing potential for treating cutaneous T-cell lymphoma and other blood disorders.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Denileukin diftitox is a fusion protein targeting the IL-2 receptor.
- The IL-2 receptor is present on activated immune cells and some hematologic malignancies.
- Specific isoforms of the IL-2 receptor are overexpressed in certain leukemias and lymphomas.
Purpose of the Study:
- To examine the clinical profile of denileukin diftitox.
- To evaluate the potential benefits of denileukin diftitox in hematologic disorders.
- To understand the mechanism of action of denileukin diftitox.
Main Methods:
- Ex vivo studies assessing interaction with IL-2 receptor isoforms.
- Internalization and intracellular release of diphtheria toxin.
- Inhibition of cellular protein synthesis leading to cell death.
Main Results:
- Denileukin diftitox binds to high- and intermediate-affinity IL-2 receptors.
- Internalization and subsequent release of active diphtheria toxin into the cytosol.
- Demonstrated cytotoxicity against cells expressing IL-2 receptor components.
Conclusions:
- Denileukin diftitox exhibits a targeted mechanism against IL-2 receptor-expressing cells.
- The drug's ability to induce protein synthesis inhibition leads to rapid cell death.
- Potential therapeutic benefits for cutaneous T-cell lymphoma and other hematologic malignancies are suggested.